Hereditary breast cancer: genetic etiology and current possibilities of prevention and surgical treatment
Authors:
Alena Puchmajerová 1,3; Jannis Tornikidis 2; Lubor Mrňa 2; Markéta Havlovicová 1; Markéta Vlčková 1; Jana Chrudimská 1; Milan Macek jr. 1; Jiří Hoch 2
Authors place of work:
Ústav biologie a lékařské genetiky 2. LF UK a FN Motol, Praha
1; Chirurgická klinika 2. LF UK a FN Motol, Praha
2; GENNET, s. r. o., Praha
3
Published in the journal:
Čas. Lék. čes. 2018; 157: 90-95
Category:
Review Article
Summary
Cancer is the second most common cause of death in our population just after cardiovascular diseases, since each third individual will become affected by it during their lifetime. Breast cancer is the most common malignancy in women. The lifetime cumulative risk of breast cancer in women under the age of 75 is around 8 % according to Czech statistics. In 70–75 % of all individuals sporadic breast carcinomas are found, with 5–10 % of all women suffer from the hereditary breast and ovarian cancer (HBOC) syndrome.
Radical, bilateral, removal of the mammary gland is the most effective prevention of breast cancer in BRCA positive women. We present a summary of 37 BRCA positive Czech patients who underwent prophylactic bilateral mastectomy and whose mean age was 46.5 years. Surgical solution is currently the only effective therapeutic way to prevent breast cancer in BRCA positive women with high genetic risk. The cosmetic consequences of this radical surgery can be solved through many reconstruction tasks.
Keywords:
breast cancer, inheritance, BRCA1, BRCA2, TP53, surgical solutions
Zdroje
1. Foretová L, Macháčková E, Palácová M et al. Doporučení rozšíření indikačních kritérií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádorů prsu a ovarií. Klinická onkologie 2016; 29 (Suppl. 1): S9–C13.
2. Kapoor NS, Curcio LD, Blakemore CA et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol 2015; 22(10): 3282–3288.
3. Gracia-Aznares FJ, Fernandez V, Pita G et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 2013; 8(2): e55681.
4. Matulonis UA, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer 2016; 122(12): 1844–1852.
5. Ledermann JA, Harter P, Gourley C et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016; 17(11): 1579–1589.
6. Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013; 3: 237.
7. Petráková K, Palácová M, Schneiderová M, Standara M. Syndrom hereditárního karcinomu prsu a ovarií. Klinická onkologie 2016; 29(Suppl.): S14–S21.
8. Mavaddat N, Peock S, Frost D et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105(11): 812–822.
9. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Ardinger HH, Pagon RA (eds.). GeneReviews. University of Washington, Seattle, 1993–2018.
10. Mersch J, Jackson MA, Park M et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015; 121(14): 269–275.
11. Moran A, O’Hara C, Khan S et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012; 11(2): 235–242.
12. Tun NM, Villani G, Ong K et al. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clin Genet 2014; 85(1): 43–48.
13. National Comprehensive Cancer Network. NCCN Guidelines, version 2.2017. BRCA-related breast and/or ovarian cancer syndrome. Dostupné na: www.nccn.org/professionals/physician_gls/f_guidelines.asp
14. Smith A, Moran A, Boyd MC et al. Phenocopies in BRCA1 and BRCA2 families evidence for modifier genes and implications for screening. J Med Genet 2007; 44: 10–15.
15. Česká onkologická společnost ČLS JEP. Odhad rizika nádoru. Dostupné na: www.linkos.cz/geneticka-rizika-vzniku-nadoru/odhad-rizika-nadoru
16. Lowry KP, Lee JM, Kong CY et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer 2012; 118(8): 2021–2030.
17. Bick U. Intensified surveillance for early detection of breast cancer in high-risk patients. Breast Care 2015; 10(1): 13–20.
18. Phi XA, Houssami N, Obdeijn M et al. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis. J Clin Oncol 2015; 33(4): 349–356.
19. Zikán M. Gynekologická prevence a gynekologické aspekty péče u nosiček mutací genů BRCA1 a BRCA2. Klinická onkologie 2016; 29(Suppl.): S22–S30.
20. Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 2013; 24(8): 2029–2035.
21. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633–1637.
Štítky
Addictology Allergology and clinical immunology Anaesthesiology, Resuscitation and Inten Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric dermatology & STDs Paediatric gastroenterology Paediatric gynaecology Paediatric surgery Paediatric cardiology Paediatric nephrology Paediatric neurology Paediatric clinical oncology Paediatric ENT Paediatric pneumology Paediatric psychiatry Paediatric radiology Paediatric rheumatology Paediatric urologist Diabetology Endocrinology Pharmacy Clinical pharmacology Physiotherapist, university degree Gastroenterology and hepatology Medical genetics Geriatrics Gynaecology and obstetrics Haematology Hygiene and epidemiology Hyperbaric medicine Vascular surgery Chest surgery Plastic surgery Surgery Medical virology Intensive Care Medicine Cardiac surgery Cardiology Clinical speech therapy Clinical microbiology Nephrology Neonatology Neurosurgery Neurology Nuclear medicine Nutritive therapist Obesitology Ophthalmology Clinical oncology Orthodontics Orthopaedics ENT (Otorhinolaryngology) Anatomical pathology Paediatrics Pneumology and ftiseology Burns medicine Medical assessment General practitioner for children and adolescents Orthopaedic prosthetics Clinical psychology Radiodiagnostics Radiotherapy Rehabilitation Reproduction medicine Rheumatology Nurse Sexuology Forensic medical examiner Dental medicine Sports medicine Toxicology Traumatology Trauma surgery Urology Laboratory Home nurse Phoniatrics Pain management Health Care Dental Hygienist Medical studentČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Non-opioid analgesics
- Pathophysiology of pain and its clinical application
- Opioids and new trends in pain therapy
- Back pain treatment